- Home
- PIII vs AKTX Comparison
PIII vs AKTX Comparison
Compare PIII & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- AKTX
- Stock Information
- Founded
- PIII 2015
- AKTX N/A
- Country
- PIII United States
- AKTX United States
- Employees
- PIII N/A
- AKTX 12
- Industry
- PIII Medical/Nursing Services
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- AKTX Health Care
- Exchange
- PIII Nasdaq
- AKTX Nasdaq
- Market Cap
- PIII 21.4M
- AKTX 35.7M
- IPO Year
- PIII N/A
- AKTX N/A
- Fundamental
- Price
- PIII $6.23
- AKTX $1.14
- Analyst Decision
- PIII Buy
- AKTX
- Analyst Count
- PIII 2
- AKTX 0
- Target Price
- PIII $16.25
- AKTX N/A
- AVG Volume (30 Days)
- PIII 3.7K
- AKTX 25.6K
- Earning Date
- PIII 08-06-2025
- AKTX 08-18-2025
- Dividend Yield
- PIII N/A
- AKTX N/A
- EPS Growth
- PIII N/A
- AKTX N/A
- EPS
- PIII N/A
- AKTX N/A
- Revenue
- PIII $1,485,192,000.00
- AKTX N/A
- Revenue This Year
- PIII N/A
- AKTX N/A
- Revenue Next Year
- PIII $7.92
- AKTX N/A
- P/E Ratio
- PIII N/A
- AKTX N/A
- Revenue Growth
- PIII 9.79
- AKTX N/A
- 52 Week Low
- PIII $6.00
- AKTX $0.85
- 52 Week High
- PIII $32.54
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- PIII 42.33
- AKTX 43.82
- Support Level
- PIII $6.00
- AKTX $1.10
- Resistance Level
- PIII $6.46
- AKTX $1.18
- Average True Range (ATR)
- PIII 0.21
- AKTX 0.05
- MACD
- PIII 0.07
- AKTX 0.00
- Stochastic Oscillator
- PIII 33.33
- AKTX 39.52
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.